1.
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
by Sun, Feng, PhD
Clinical therapeutics, 2015, Vol.37 (1), p.225-241.e8
2.
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
by Nagashima, M
Diabetologia, 2011-07-24, Vol.54 (10), p.2649-2659
3.
Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice
by Kooijman, Sander
Diabetologia, 2015, Vol.58 (11), p.2637-2646
4.
Cardiovascular Effects of Glucagonlike peptide–1 Agonists
by Davidson, Michael H., MD
The American journal of cardiology, 2011, Vol.108 (3), p.33B-41B
5.
Cardiovascular Effects of Incretin-Based Therapies
by White, William B
Annual review of medicine, 2016-01-14, Vol.67 (1), p.245-260
6.
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
by Neumiller, Joshua J., PharmD, CDE, CGP, FASCP
Clinical therapeutics, 2011, Vol.33 (5), p.528-576
7.
Incretin Effect After Oral Amino Acid Ingestion in Humans
by Lindgren, Ola
The journal of clinical endocrinology and metabolism, 2015-03, Vol.100 (3), p.1172-1176
8.
Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors
by Chrysant, Steven G., MD, PhD
The American journal of cardiology, 2012, Vol.109 (11), p.1681-1685
9.
Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism...
by Padrutt, I
Research in veterinary science, 2015-04, Vol.99, p.23-29
10.
Incretin treatment and atherosclerotic plaque stability: Role of adiponectin/APPL1 signaling pathway
by Barbieri, Michelangela
Journal of diabetes and its complications, 2016, Vol.31 (2), p.295-303
11.
Pseudoislet formation enhances gene expression, insulin secretion and cytoprotective mechanisms of clonal human insulin-secreting 1.1B4 cells
by Green, Alastair D
Pflügers Archiv, 2015-01-06, Vol.467 (10), p.2219-2228
12.
Ongoing Clinical Trials Evaluating the Cardiovascular Safety and Efficacy of Therapeutic Approaches to Diabetes Mellitus
by Fonseca, Vivian A., MD
The American journal of cardiology, 2011, Vol.108 (3), p.52B-58B
13.
Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect i...
by Vardarli, Irfan
The journal of clinical endocrinology and metabolism, 2011-04, Vol.96 (4), p.945-954
14.
The Gut: A Key to the Pathogenesis of Type 2 Diabetes?
by Holst, Jens Juul
Metabolic syndrome and related disorders, 2017-08-01, Vol.15 (6), p.259-262
15.
Disruption of CR6-interacting factor-1 (CRIF1) in mouse islet beta cells leads to mitochondrial diabetes with progressive beta cell failure
by Kim, Yong Kyung
Diabetologia, 2015-02-08, Vol.58 (4), p.771-780
16.
Incretin-based therapies and cardiovascular risk
by Mannucci, Edoardo
Current medical research and opinion, 2012-05, Vol.28 (5), p.715-721
17.
Understanding the Incretin Effect
by Seino, Yutaka
The journal of clinical endocrinology and metabolism, 2011-04, Vol.96 (4), p.934-935
18.
Incretins and thiazolidinediones in glucose homeostasis and cancer: Role of common polymorphisms
by Arora, Shitij
Cancer letters, 2012, Vol.323 (2), p.128-134
19.
Minireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1
by Brubaker, Patricia L
Endocrine reviews, 2010-04, Vol.31 (2), p.262-262
20.
Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
by Marathe, Chinmay S.
Experimental diabetes research, 2011-06-22, Vol.2011, p.279530-10
